Risk Management Cloud Rains On Praecis, Offers Silver Lining To Novartis
Executive Summary
Brand loyalty stemming from Novartis' risk management program for Clozaril (clozapine) has limited generic erosion for the antipsychotic, Novartis Medical Information & Communication Exec Director Tom Gesell said
You may also be interested in...
Novartis Clozaril, Generic Registry Merger Could Clarify Potential Risk
Combining Novartis' Clozaril white blood cell patient registry with generic clozapine databases could provide a clearer picture of the potential risk of moving to a less frequent monitoring schedule, FDA's Psychopharmacologic Drugs Advisory Committee agreed June 16
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials